Operator
Good day, and welcome to the iAcess Alpha Virtual Best Ideas Fall Investment Conference 2026. Our next presenting company is Dyadic Applied Biosolutions. [Operator Instructions]
I’d now like to turn the floor over to today’s host, Joe Hazelton, President and COO at Dyadic Applied Biosolutions. Please go ahead.
Joseph Hazelton
President & COO
Thank you, and thank you, everyone, for joining us today. Again, my name is Joe Hazelton. I’m the President and Chief Operating Officer for Dyadic Applied Biosolutions. And I spent about the last 30 years in biopharmaceutical commercialization and development before 3 years ago joining Dyadic to help with the commercialization of their platform technology across 3 core areas: life sciences; food nutrition; and Bioindustrial. And what I’m really excited about is we’re now at the commercial stage. So we’ve transitioned from a true R&D organization into a commercial organization with multiple products either on the market or in current commercialization using our gene expression technology.
Now we’re going to — wait for the slide — oh, there we go. So I’m going to be making, obviously, certain forward-looking statements. Please refer to our risk profiles and our SEC documents found on our website. And let’s talk about why Dyadic is exciting right now, and it’s really because of the growth and the demand for proteins worldwide, specifically animal-free solutions. So as we look, the global demand for protein is growing across all 3 of our key segments: life sciences; food and nutrition; and bioindustrial for multiple different reasons. Not only from a food and nutrition standpoint, we have a growing population. In the life sciences, companies are looking for safer, more reliable alternatives to animal or plant-derived proteins. And when you use recombinant or nonanimal solutions, you can have broader
